대한암한의학회지 (Journal of Korean Traditional Oncology)

  • 제22권1호
  • /
  • Pages.13-22
  • /
  • 2017
  • /
  • 1975-244X(pISSN)
  • /
  • 2765-4850(eISSN)
대한암한의학회 (Korean Association of Traditional Oncology)
권호 표지
DOI QR코드

DOI QR Code

노봉상기정을 투여하여 Olmutinib으로 인한 피부염이 호전된 4기 비소세포성 폐암 환자 1례

A Case of Non-Small Cell Lung Carcinoma Patient Who Improved Skin Rash Due to Olmutinib by Administration of Nobongsangki-Jeong

  • 최유나 (대전대학교 둔산한방병원 동서암센터) ;
  • 김지혜 (대전대학교 둔산한방병원 동서암센터) ;
  • 배겨레 (대전대학교 둔산한방병원 동서암센터) ;
  • 조종관 (대전대학교 둔산한방병원 동서암센터) ;
  • 유화승 (대전대학교 둔산한방병원 동서암센터)
  • Choi, You-Na (East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Kim, Jeehye (East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Bae, Kyeore (East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Cho, Chong-kwan (East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Yoo, Hwa-Seung (East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University)
  • 투고 : 2017.05.02
  • 심사 : 2017.06.10
  • 발행 : 2017.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: The purpose of this study is to report the effect of Nobongsangki-Jeong on skin rash caused by Olmutinib. Methods: A female Non-Small cell lung carcinoma patient (Adenocarcinoma, Stage IV, Epidermal Growth Factor Receptor positive) suffered from skin rash due to the side effect of Olmutinib administration. She was treated with Nobongsangki-Jeong for the symptom management for 14 days. The clinical outcomes were measured by numeric rating scale (NRS) and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Results: After treatment, skin rash was improved from NRS 5 to 1. Pruritus and pain of skin were improved from NCI-CTCAE grade 2 to 1. Conclusion: This case study suggests that Nobongsangki-Jeong may have the efficacy for the treatment of skin rash caused by Olmutinib.

키워드

참고문헌

  1. 보건복지부, 중앙암등록본부, 국립암센터. 국가암등록사업 연례보고서(2014년 암등록통계). 2016
  2. Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) 7(3):1815-1846, 2015 https://doi.org/10.3390/cancers7030864
  3. Xu M, Xie Y, Ni S, Liu H. The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer. Ann Transl Med 3(7):96, 2015 https://doi.org/10.3978/j.issn.2305-5839.2015.03.60
  4. Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M, de Marinis F. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacol Res 117:406-415, 2017 https://doi.org/10.1016/j.phrs.2017.01.003
  5. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141-151, 2015 https://doi.org/10.1016/S1470-2045(14)71173-8
  6. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16(8):897-907, 2015 https://doi.org/10.1016/S1470-2045(15)00006-6
  7. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17(5):577-589, 2016 https://doi.org/10.1016/S1470-2045(16)30033-X
  8. Saveria Pasto re, France sca M ascia, Valentina Mariani, Giampiero Girolomoni. The Epidermal Growth Factor Receptor System in Skin Repair and Inflammation, Journal of Investigative Dermatology 128(6):1365-1374, 2008 https://doi.org/10.1038/sj.jid.5701184
  9. Hirsh V Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer, Curr Oncol 18(3):126-138, 2011
  10. Ogawa Y, Kiba T, Nakano K, Fujiwara K, Taniguchi H, Hosokawa A, Nakashima T, Kimoto S, Kajiume S, Okada Y, Ichiba Y. Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib, Gan To Kagaku Ryoho, 41(4):517-522, 2014
  11. 박재우, 전형준, 조종관, 이연월. One Case Study of a Non Small Cell Lung Cancer Patient Experiencing Gefitinib Adverse Effects Managed by Traditional Korean Medicine, 대한암한의학회지, 17(1):9-16, 2012
  12. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4.0, 2010. Available at http://evs.nci.nih.gov/ftp1/CTCAE/About.html
  13. Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) 7(3):1815-1846, 2015 https://doi.org/10.3390/cancers7030864
  14. 김민경, 이진수, 이상헌, 정현식, 최원철, 김경석. A Clinical Case of Patient with Cancer Pain Treated by Moxibustion, 대한암한의학회지, 14(1):53-59
  15. 강지영, 김준영, 손창규, 조정효. Long-Term Survival of Patients with Lung Cancer Treated by Traditional Korean Medicine Combined with Western Treatment : Report of Two Cases, 대한한방내과학회지 36(1): 58-68, 2015
  16. 김기숙, 강상모. The Skin Safety and Effects of the Fermented Broth of Lactobacillus Rhamnosus for Improving the Neck Skin, 한국미용학회지 23(1):101-115, 2017
  17. 강석성. The adhesive characteristics of Lactobacillus fermentum VRI 003 to Peyer's patches and its effect on the immune response in mice, University of New South Wales, 1-194, 2013
  18. 장재식, 정지천, 신현철. Effects of Vespae Nidus on Peroxynitrite Production and Protein Expression of Proinflammatory Mediators, 동의생리병리학회지 21(6):1499-1505, 2007
  19. 송정방, 김재효, 김유리, 박유리, 안성훈, 손인철. TNBS로 유도된 흰쥐의 대장염에 대한 노봉방 약침의 효과, 경락경혈학회지, 26(4):195-209, 2009